Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program

Summary

Nurix Therapeutics and Gilead Sciences have extended their oncology research collaboration for an additional two years. The agreement represents a continuation of their existing research partnership in the oncology space.